^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: MK-2870, SKB 264, SKB264, sac-TMT, SKB-264, MK2870, MK 2870
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    3d
    OptiTROP-Breast01: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=254, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 --> Jun 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + HR positive + BRCA mutation
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    7d
    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)
    7d
    Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer. (PubMed, Iran J Pharm Res)
    This review summarizes a range of ADCs targeting tumor-associated antigens in ovarian cancer, including mirvetuximab soravtansine (MIRV), trastuzumab deruxtecan (T-DXd), datopotamab deruxtecan (Dato-DXd), sacituzumab tirumotecan (SKB-264), PF-06664178, anetumab ravtansine (BAY 94-9343), BMS-986148, DMOT4039A, RC88, lifastuzumab vedotin (DNIB0600A), upifitamab rilsodotin (ABBV-181), ZW220, DMUC4064A, and sofituzumab vedotin (DMUC5754A). The ADCs hold significant potential to reshape the treatment landscape for ovarian cancer by providing targeted therapeutic options. Further research is required to optimize patient selection, address resistance mechanisms, and improve safety profiles.
    Review • Journal
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Elahere (mirvetuximab soravtansine-gynx) • budigalimab (ABBV-181) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan) • anetumab ravtansine (BAY 94-9343) • upifitamab rilsodotin (XMT-1536) • RG7600 • lifastuzumab vedotin (DNIB0600A) • RG7882 • ZW220 • BMS-986148
    10d
    A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (clinicaltrials.gov)
    P3, N=1023, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Jiataile (sacituzumab tirumotecan)
    11d
    SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=89, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab)
    16d
    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=38, Recruiting, Merck Sharp & Dohme LLC | N=98 --> 38 | Trial completion date: Jul 2028 --> Mar 2028 | Trial primary completion date: Jul 2028 --> Mar 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)
    18d
    Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    18d
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2028 --> Jun 2028 | Trial primary completion date: Oct 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • Jiataile (sacituzumab tirumotecan) • Tivdak (tisotumab vedotin-tftv)
    18d
    Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • Jiataile (sacituzumab tirumotecan)
    19d
    Sacituzumab Tirumotecan in Participants With Advanced or Metastatic Urothelial Carcinoma and Disease Progression after Chemotherapy and Immune Checkpoint Inhibitors. (PubMed, Ann Oncol)
    Sac-TMT 5 mg/kg monotherapy every 2 weeks demonstrated promising antitumor activity in participants with heavily pretreated advanced or metastatic UC, with a manageable safety profile, warranting further evaluation of sac-TMT in this population.
    Journal • Checkpoint inhibition
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Jiataile (sacituzumab tirumotecan)
    23d
    Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences. (PubMed, Cancer Chemother Pharmacol)
    There are differences in pharmacological effects, efficacy, and incidence of adverse events among sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan. For patients with EGFR-mutated progression after targeted therapy or driver gene negative advanced non-small cell lung cancer, the individualized optimization of TROP2 ADCs treatment can obtain the greatest benefit.
    Review • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)
    25d
    OptiTROP-Lung04: A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients (clinicaltrials.gov)
    P3, N=376, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR mutation
    |
    cisplatin • carboplatin • pemetrexed • Jiataile (sacituzumab tirumotecan)